NewcelX Ltd. - Ordinary Shares (NCEL)
NCEL moved a median of +0.13% 30 minutes after news, and -1.50% by the close. How NCEL actually reacts to news — the realized, point-in-time move the market made, measured across 62 labeled events over the last three years with zero look-ahead.
NCEL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 47 |
| 30-min | +0.13% | 56% | 59 |
| 60-min | +0.94% | 57% | 60 |
| to close | -1.50% | 37% | 60 |
| Middle 50% of NCEL reactions | -2.96% to +2.26% |
|---|---|
| Median reaction (30-min) | +0.13% |
| Measured reactions | 62 |
Half of all NewcelX Ltd. - Ordinary Shares news events land between -2.96% and +2.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NCEL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NCEL's baseline. Nothing else.
Recent NCEL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | Press release | GlobeNewswire | +5.23% | +1.74% | |
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.72% | |
| Form 6-K NewcelX Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.40% | -8.05% | |
| Form POS AM NewcelX Ltd. | SEC filing · Form POS | SEC EDGAR | +0.40% | -8.05% | |
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +4.12% | +4.59% | |
| Form D NewcelX Ltd. | SEC filing · Form D | SEC EDGAR | — | +0.58% | |
| Form F-3 NewcelX Ltd. | SEC filing · Form F-3 | SEC EDGAR | — | -1.73% | |
| Form 6-K NewcelX Ltd. For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | +4.32% | -0.58% | |
| Form 6-K NewcelX Ltd. For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.45% | |
| NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | Press release | GlobeNewswire | +0.00% | +1.45% | |
| Form 6-K NewcelX Ltd. For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | — | -0.88% | |
| NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio | Press release | GlobeNewswire | -3.56% | -3.44% | |
| Form 6-K NewcelX Ltd. For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | -1.38% | +5.75% | |
| NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | Press release | GlobeNewswire | -1.38% | +5.75% | |
| Form 6-K NewcelX Ltd. For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | -16.05% | -4.94% | |
| NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | Press release | GlobeNewswire | -13.70% | -2.28% | |
| Form 6-K NewcelX Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -13.92% | -2.53% | |
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +5.08% | |
| Form 6-K NewcelX Ltd. For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | +2.80% | -0.31% | |
| Form F-3/A NewcelX Ltd. | SEC filing · Form F-3 | SEC EDGAR | +2.12% | +6.39% | |
| Form 6-K NewcelX Ltd. For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +14.09% | |
| Form 6-K NewcelX Ltd. For: May 27 | SEC filing · Form 6-K | SEC EDGAR | -3.48% | +0.00% | |
| NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | Press release | GlobeNewswire | -3.48% | +0.00% | |
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -3.12% | |
| Form D NewcelX Ltd. | SEC filing · Form D | SEC EDGAR | — | -2.12% | |
| Form F-3 NewcelX Ltd. | SEC filing · Form F-3 | SEC EDGAR | +0.00% | +2.15% | |
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +1.22% | -1.22% | |
| Form POS AM NewcelX Ltd. | SEC filing · Form POS | SEC EDGAR | +3.11% | -6.21% | |
| Form 6-K NewcelX Ltd. For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | -1.57% | +15.14% | |
| NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | Press release | GlobeNewswire | -1.57% | +15.14% | |
| Form 20-F NewcelX Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -1.57% | +15.14% | |
| Form 6-K NewcelX Ltd. For: Apr 20 | SEC filing · Form 6-K | SEC EDGAR | +3.00% | +5.99% | |
| NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | Press release | GlobeNewswire | +3.00% | +5.99% | |
| Form 6-K NewcelX Ltd. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.96% | |
| NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | Press release | GlobeNewswire | +2.60% | +1.73% | |
| Form 6-K NewcelX Ltd. For: Mar 09 | SEC filing · Form 6-K | SEC EDGAR | -0.67% | -7.74% | |
| NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | Press release | PR Newswire | -0.67% | -7.74% | |
| Form 6-K NewcelX Ltd. For: Feb 12 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.10% | |
| NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy | Press release | PR Newswire | +0.00% | -2.10% | |
| Form 6-K NewcelX Ltd. For: Jan 29 | SEC filing · Form 6-K | SEC EDGAR | +4.03% | -14.43% | |
| NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences | Press release | PR Newswire | +4.03% | -14.43% | |
| Form 6-K NewcelX Ltd. For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | -1.64% | +2.05% | |
| NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | Press release | PR Newswire | -1.64% | +2.05% | |
| Form 6-K NewcelX Ltd. For: Jan 05 | SEC filing · Form 6-K | SEC EDGAR | -0.42% | -5.51% | |
| NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board | Press release | PR Newswire | -0.42% | -5.51% | |
| Form 6-K NewcelX Ltd. For: Dec 11 | SEC filing · Form 6-K | SEC EDGAR | -3.57% | -20.71% | |
| NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China | Press release | PR Newswire | -3.57% | -20.71% | |
| Form 6-K NewcelX Ltd. For: Nov 20 | SEC filing · Form 6-K | SEC EDGAR | +3.48% | +3.48% | |
| NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute | Press release | PR Newswire | +2.01% | +0.00% | |
| NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board | Press release | PR Newswire | -2.91% | -10.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NCEL section they belong to.
Where else NCEL is measured.
NCEL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NewcelX Ltd. - Ordinary Shares's median reaction calculated?
Every labeled NCEL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 62 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of NCEL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NCEL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.